Dezhan Healthcare

Explore the latest insights on Dezhan Healthcare and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Dezhan Healthcare’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Huadong Medicine's Oral GLP‑1 Agonist HDM1002 Delivers Positive Phase III Results for Weight Management – Pre‑NDA Complete, China Marketing Application Imminent
CompanyDrug

Huadong Medicine’s Oral GLP‑1 Agonist HDM1002 Delivers Positive Phase III Results for Weight Management – Pre‑NDA Complete, China Marketing Application Imminent

Huadong Medicine Co., Ltd. (SHE: 000963) announced positive topline results from its Phase III clinical study (HDM1002‑301) evaluating HDM1002 tablets (Conveglipron Trometamol Tablets), a Class 1 oral small‑molecule GLP‑1 receptor…

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now